Patient-reported quality of life during PARP-inhibitor treatment for high-grade serous ovarian cancer (468)

Abstract

<b>Objectives:</b> To determine the impact of PARP inhibitor maintenance treatment on the health-care quality of life (QOL) of women with high-grade serous ovarian cancer after cytoreductive surgery. <b>Methods:</b> Patient-reported outcome (PRO) collection was implemented at our gynecologic oncology clinic in January 2018. At serial visits, patients were administered general oncology and diseasespecific PRO measures (PROMs) based on the patient disease site. All patients with ovarian cancer (OC) were then identified, and data on PARP inhibitor use was collected from the electronic health records. The date of cytoreductive surgery, as well as initiation of PARP inhibitor therapy, were noted. Specific PROM questions reflecting the quality of life were selected a priori from questionnaires for analysis, and health-related quality of life was compared pre- and post- PARP inhibitor therapy and between patients who were and were not treated with PARP inhibitors. <b>Results:</b> Between January 2018 and July 2020, 285 patients with ovarian cancer were identified who had both undergone cytoreductive surgery and completed PROMs. From these 285 patients, 1275 individual PROMs responses were available for analysis. Seventy- three patients from the cohort had been started on PARP inhibitor maintenance therapy postoperatively. Utilizing the quality-of-life items within the EORTC-QLQ C-30, patients reported an initial drop in quality of life after initiation of PARP inhibitor therapy (Figure 1 A). However, with increasing duration of PARP inhibitor use, patients reported an improvement in their quality of life which surpassed pre-treatment levels at 180 days post-initiation (Figure 1A). When patients who received PARPs were compared to those who did not, the quality of life in the PARP-inhibitor group was worse during the first six postoperative months (Figure 1B). However, at one year post- operatively, the quality of life in the two groups was equal (Figure 1B). <b>Conclusions:</b> PARP inhibitor use is associated with an initial reduction in healthcare quality of life in patients with high-grade serous ovarian cancer. However, with increasing duration of use, quality of life surpasses pre-treatment levels and is equal to that of patients who are not receiving PARP inhibitor therapy by one year postopera- tively. This study confirms the tolerability of PARP inhibitor maintenance therapy in women with high-risk ovarian cancer.